|
Bortezomib
|
DB00188 |
[Bortezomib (originally PS-341 and marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans. The boron atom within bortezomib catalytically binds the active site of the 26S proteasome with high affinity and specificity, thereby resulting in cell cycle arrest and apoptosis. In normal cells, the proteasome is involved in degradation of ubiquitylated proteins that have been tagged for destruction because they are damaged or unneeded by the cell. However, in cancerous cells, proteasome activity degrades pro-apoptotic proteins such as p53 that would normally result in programmed cell death of the dysfunctional cells. Proteasome inhibitors such as bortezomib interrupt this process, resulting in destruction of cancerous cells. Bortezomib is currently approved in the United States for the treatment of relapsed multiple myeloma and mantle cell lymphoma.] |
|
Esmolol
|
DB00187 |
[Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions. Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine.] |
|
Auriclosene
|
DB12197 |
[Auriclosene has been used in trials studying the treatment of Impetigo, Bacterial Conjunctivitis, Asymptomatic Bacteriuria, and Adenoviral Conjunctivitis.] |
|
Fosdagrocorat
|
DB12198 |
[Fosdagrocorat has been used in trials studying the treatment and basic science of Rheumatoid Arthritis.] |
|
TRV-120027
|
DB12199 |
[TRV120027 has been used in trials studying the treatment of Heart Failure and Kidney Disease.] |
|
Ajulemic acid
|
DB12193 |
[Ajulemic acid has been used in trials studying the treatment of Cystic Fibrosis, Dermatomyositis, and Diffuse Cutaneous Systemic Sclerosis.] |
|
Atamestane
|
DB12194 |
[Atamestane has been used in trials studying the treatment of Breast Cancer, Breast Neoplasms, and Neoplasms, Hormone-Dependent.] |
|
VP-14637
|
DB12195 |
[MDT-637 has been investigated for the treatment of Drug Safety.] |
|
CP-866087
|
DB12196 |
[CP-866,087 has been used in trials studying the treatment of Obesity, Alcoholism, and Sexual Dysfunction, Physiological.] |
|
Faropenem
|
DB12190 |
[Faropenem has been used in trials studying the treatment of Tuberculosis, Pulmonary Tuberculosis, and Community Acquired Pneumonia.] |
|
Obatoclax
|
DB12191 |
[Obatoclax has been used in trials studying the treatment of AML, Leukemia, Myelofibrosis, Hodgkin's Lymphoma, and Mantle-Cell Lymphoma, among others.] |
|
Emeramide
|
DB12192 |
[Emeramide has been used in trials studying the treatment of Mercury Poisoning.] |
|
Trifluorofurnesyl Diphosphate
|
DB02808 |
|
|
Brodimoprim-4,6-Dicarboxylate
|
DB02809 |
[Brodimoprim-4,6-dicarboxylate is a solid. This compound belongs to the anisoles. These are organic compounds contaiing a methoxybenzene or a derivative thereof. This medication is known to target the protein dihydrofolate reductase.] |
|
5-Exo-Hydroxycamphor
|
DB02817 |
|
|
Iodo-Willardiine
|
DB02818 |
|
|
7-(1-Methyl-1,2,3-Triazol-4-Yl)-6-Formyl-2,7-Dihydro-[1,4]Thiazepine-3-Carboxylic Acid, Brl42715, C6-(N1-Methyl-1,2,3-Triazolylmethylene)Penem
|
DB02816 |
|
|
2-Acetamido-2-Deoxy-D-Glucono-1,5-Lactone
|
DB02813 |
|
|
3'-Deazo-Thiamin Diphosphate
|
DB02814 |
|
|
Diethylphosphono Group
|
DB02811 |
|
